View Item 

Show simple item record

Clinical and Economic Effectiveness of an Inpatient Anticoagulation Service

dc.contributor.authorMamdani, Muhammad M.en_US
dc.contributor.authorRacine, Ericen_US
dc.contributor.authorMcCreadie, Scotten_US
dc.contributor.authorZimmerman, Chrisen_US
dc.contributor.authorO'Sullivan, Tami L.en_US
dc.contributor.authorJensen, Gailen_US
dc.contributor.authorRagatzki, Paulen_US
dc.contributor.authorStevenson, James G.en_US
dc.date.accessioned2012-03-16T15:57:58Z
dc.date.available2012-03-16T15:57:58Z
dc.date.issued1999-09en_US
dc.identifier.citationMamdani, Muhammad M.; Racine, Eric; McCreadie, Scott; Zimmerman, Chris; O'Sullivan, Tami L.; Jensen, Gail; Ragatzki, Paul; Stevenson, James G. (1999). "Clinical and Economic Effectiveness of an Inpatient Anticoagulation Service." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 19(9). <http://hdl.handle.net/2027.42/90256>en_US
dc.identifier.issn0277-0008en_US
dc.identifier.issn1875-9114en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/90256
dc.publisherBlackwell Publishing Ltden_US
dc.publisherWiley Periodicals, Inc.en_US
dc.titleClinical and Economic Effectiveness of an Inpatient Anticoagulation Serviceen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumCollege of Pharmacy, University of Michigan, Ann Arbor, Michigan.en_US
dc.contributor.affiliationumUniversity of Michigan Medical Center, Ann Arbor, Michigan.en_US
dc.contributor.affiliationotherInstitute for Clinical Evaluation Sciences and the University of Toronto, Toronto, Ontario, Canadaen_US
dc.contributor.affiliationotherCollege of Pharmacy and Allied Health Professions, Wayne State University, Detroit, Michiganen_US
dc.contributor.affiliationotherDepartment of Economics, Wayne State University, Detroit, Michigan.en_US
dc.contributor.affiliationotherSchool of Medicine, Wayne State University, Detroit, Michigan.en_US
dc.contributor.affiliationotherDepartment of Pharmacy, Harper Hospital, Detroit Medical Center, Detroit, Michiganen_US
dc.contributor.affiliationotherDetroit Receiving Hospital, Detroit Medical Center, Detroit, Michigan.en_US
dc.contributor.affiliationotherDepartment of Pharmacy, Henry Ford Hospital, Detroit, Michigan.en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/90256/1/phco.19.13.1064.31591.pdf
dc.identifier.doi10.1592/phco.19.13.1064.31591en_US
dc.identifier.sourcePharmacotherapy: The Journal of Human Pharmacology and Drug Therapyen_US
dc.identifier.citedreferenceClagett GP, Reisch JS. Prevention of venous thromboembolism. Chest 1992; 102: 391S – 407.en_US
dc.identifier.citedreferenceGoldhaber S.. Thrombolysis for pulmonary embolism. Prog Cardiovasc Dis 1991; 34: 113 – 34.en_US
dc.identifier.citedreferenceSalzman EW, Hirsh J.. The epidemiology, pathogenesis and natural history of venous thromboembolism. In: Coleman RW, Hirsh J., Marder VJ, Salzman EW, eds. Hemostasis and thrombosis. Philadelphia: JB Lippincott, 1994: 1275 – 96.en_US
dc.identifier.citedreferenceAnderson FA Jr, Wheeler HB, Goldberg RJ, et al. A population‐based perspective of the hospital incidence and the case‐fatality rates of deep vein thrombosis and pulmonary embolism: the Worcester DVT study. Arch Intern Med 1991; 151: 933 – 8.en_US
dc.identifier.citedreferenceHirsh J., Raschke R., Warkentin TE, Dalen JE, Deykin D., Poller L.. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1995; 108 ( 4 ): 258S – 75.en_US
dc.identifier.citedreferenceHull RD, Raskob GE, Hirsh J., et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal deep vein thrombosis. N Engl J Med 1986; 315: 1109 – 14.en_US
dc.identifier.citedreferenceRaschke RA, Reilly BM, Guidry J.R., Fontana J.R., Srinivas S.. The weight‐based heparin dosing nomogram compared with a “standard care” nomogram. Ann Intern Med 1993; 119: 874 – 81.en_US
dc.identifier.citedreferenceCipolle RJ, Rodvold KA. Heparin. In: Evans WE, Schentag JJ, Jusko W., eds. Applied pharmacokinetics. Spokane, WA: Applied Therapeutics, 1986: 908 – 42.en_US
dc.identifier.citedreferenceReilly BM, Raschke RA, Srinivas S., Nieman T.. Intravenous heparin dosing: patterns and variations in internists' practices. J Gen Intern Med 1993; 8: 536 – 42.en_US
dc.identifier.citedreferenceWheeler AP, Jaquiss RDB, Newman JH. Physician practices in the treatment of pulmonary embolism and deep vein thrombosis. Arch Intern Med 1988; 148: 1321 – 5.en_US
dc.identifier.citedreferenceNemeth JS, Marxen TL, Piltz GW. Weight‐based protocol for improving heparin therapy. Am J Health-Syst Pharm 1996; 53: 1164 – 6.en_US
dc.identifier.citedreferenceShalansky KF, Fitzgerald JM, Sunderji R., et al. Comparison of a weight‐based heparin nomogram with traditional heparin dosing to achieve therapeutic anticoagulation. Pharmacotherapy 1996; 16 ( 6 ): 1076 – 84.en_US
dc.identifier.citedreferenceHull RD, Raskob GE, Rosenbloom D., et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990; 322: 1260 – 4.en_US
dc.identifier.citedreferenceFennerty A., Dolben J., Thomas P., et al. Flexible induction dose regimen for warfarin and prediction of maintenance dose. Br Med J 1984; 288: 1268 – 70.en_US
dc.identifier.citedreferenceCogo A., Bernardi E., Prandoni E., et al. Acquired risk factors for deep vein thrombosis in symptomatic patients. Arch Intern Med 1994; 154: 164 – 8.en_US
dc.identifier.citedreferenceCarson JL, Kelley MA, Duff A., et al. The clinical course of pulmonary embolism. N Engl J Med 1992; 326: 1240 – 5.en_US
dc.identifier.citedreferenceSchafer AI. The hypercoaguable states. Ann Intern Med 1985; 102: 814 – 28.en_US
dc.identifier.citedreferenceHull RD, Raskob GE, Rosenbloom D., et al. Optimal therapeutic level of heparin therapy in patients with venous thromboembolism. Arch Intern Med 1992; 152: 1589 – 95.en_US
dc.identifier.citedreferenceCharlson ME, Pompei P., Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987; 40: 373 – 83.en_US
dc.identifier.citedreferenceJacobs P.. Economic measurement: cost‐benefit and cost‐effectiveness analysis. In: The economics of health and medical care, 3rd ed. Gaithersburg, MD: Aspen, 1991: 353.en_US
dc.identifier.citedreferenceZimmerman CR, Smolarek RT, Stevenson JG. A computerized system to improve documentation and reporting of pharmacists' clinical interventions, cost savings, and workload activities. Pharmacotherapy 1995; 15: 220 – 7.en_US
dc.identifier.citedreferenceFisher LD, van Belle G.. Biostatistical design of medical studies. In: Biostatistics: a methodology for the health sciences. New York: John Wiley & Sons, 1993: 18.en_US
dc.identifier.citedreferenceHennekens CH, Buring JE. Epidemiology in medicine. Boston: Little, Brown, 1987.en_US
dc.identifier.citedreferenceEllrodt AG, Conner L., Riedinger M., Weingarten S.. Measuring and improving physician compliance with clinical practice guidelines. Ann Intern Med 1995; 122: 277 – 82.en_US
dc.identifier.citedreferenceLevine M., Gent M., Hirsh J., et al. A comparison of low‐molecular‐weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep‐vein thrombosis. N Engl J Med 1996; 334: 677 – 81.en_US
dc.identifier.citedreferenceKoopman MMW, Prandoni P., Piovella F., et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low‐molecular‐weight heparin administered at home. N Engl J Med 1996; 334: 682 – 7.en_US
dc.identifier.citedreferenceAnonymous.. Informed Newsletter. Toronto, Ontario, Canada: Institute for Clinical Evaluative Sciences, Sunnybrook Medical Center 1996; 3 ( 1 ).en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
phco.19.13.1064.31591.pdf
Size:
84.91KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.